Table 2.
Summary of Genomic Testing Results of Cannabinoid Hyperemesis Syndrome Patients Versus Controls
| Gene | RSID | Mutation | Allele | Zygosity | Diplotype | Haplotype | p a | Odds ratio (confidence interval) | Control displaying variant (%) | CHS patients displaying variant |
|---|---|---|---|---|---|---|---|---|---|---|
| COMT | rs4646316 | Intron | C>T | Heterozygous | CGGC/TGGC | CGGC | 0.012 | 12 (1.3–98.1) | 10 | 57.1% |
| ABCA1 | rs2230806 | Synonymous | C>T | Homozygous | CTTG/CTTG | CTTG | 0.012 | 8.4 (1.5–48.1) | 20 | 67.9% |
| TRPV1 | rs879207 | Downstream | A>G | Heterozygous | ATGG/GTGG | ATGG | 0.015 | 5.8 (1.2–28.4) | 30 | 71.5% |
| DRD2 | rs4648318 | Intron | T>C | Heterozygous | TCCC/CCCC | TCCC | 0.031 | 6.2 (1.1–34.7) | 20 | 60.7% |
| CYP2C9 | rs1934967 | Intron | C>T | Homozygous | CTTG/CTTG | CTTG | 0.043 (0.011b) | 7.8 (1.1–70.1) | 10 | 46.4% (60%b) |
| TRPV1 | rs11655540 | Intron | T>G | Heterozygous | TCAA/GCAA | TCAA | 0.066 | 4.2 (0.8–19.9) | 30 | 64.3% |
| COMT | rs165656 | Intron | C>T | Heterozygous | CCGG/TCGG | CCGG | 0.069 | 4.6 (0.8–25.7) | 20 | 53.6% |
| CYP2C19 | rs4494250 | Intron | G>A | Heterozygous | GCTT/ACTT | GCTT | 0.069 (0.007b) | 4.6 (0.8–25.7) | 20 | 53.6% (75%b) |
| CRY1 | rs2287161 | Downstream | G>C | Heterozygous | GTCG/CTCG | GTCG | 0.091 | 3.7 (0.8–16.9) | 50 | 78.6% |
a
p-Values were obtained through a Fisher exact test. Odds ratios are shown with a 95% confidence interval.
b
Genes CYP2C9 and CYP2C19 have a second set of values showing when patients on PPI medications were excluded from the data. This was due to suspected interactions of CYP2C9 and CYP2C19 and PPI medication.